- Case report
- Open Access
A L2HGDH initiator methionine codon mutation in a Yorkshire terrier with L-2-hydroxyglutaric aciduria
© Farias et al.; licensee BioMed Central Ltd. 2012
- Received: 9 April 2012
- Accepted: 4 July 2012
- Published: 26 July 2012
L-2-hydroxyglutaric aciduria is a metabolic repair deficiency characterized by elevated levels of L-2-hydroxyglutaric acid in urine, blood and cerebrospinal fluid. Neurological signs associated with the disease in humans and dogs include seizures, ataxia and dementia.
Here we describe an 8 month old Yorkshire terrier that presented with episodes of hyperactivity and aggressive behavior. Between episodes, the dog’s behavior and neurologic examinations were normal. A T2 weighted MRI of the brain showed diffuse grey matter hyperintensity and a urine metabolite screen showed elevated 2-hydroxyglutaric acid. We sequenced all 10 exons and intron-exon borders of L2HGDH from the affected dog and identified a homozygous A to G transition in the initiator methionine codon. The first inframe methionine is at p.M183 which is past the mitochondrial targeting domain of the protein. Initiation of translation at p.M183 would encode an N-terminal truncated protein unlikely to be functional.
We have identified a mutation in the initiation codon of L2HGDH that is likely to result in a non-functional gene. The Yorkshire terrier could serve as an animal model to understand the pathogenesis of L-2-hydroxyglutaric aciduria and to evaluate potential therapies.
- L-2-hydroxyglutaric aciduria
- Yorkshire terrier
- Initiator methionine codon
L-2 hydroxyglutaric aciduria (L-2-HGA) was first described in 1980 in a young boy with psychomotor retardation and musculoskeletal dystrophy . This rare autosomal recessive inherited disease is characterized by an elevated concentration of L-2-hydroxyglutaric acid in plasma, cerebrospinal fluid, and urine . In human patients, the clinical features are mild psychomotor delay, followed by progressive cerebellar ataxia, dysarthria, moderate to severe mental deterioration and in some cases seizures [2, 3]. Magnetic resonance imaging (MRI) of L-2-HGA patients shows abnormal signal in the peripheral subcortical white matter, basal ganglia and dentate nuclei. Also, cerebellar atrophy is present. The distribution of signal abnormalities in the MRI of L-2-HGA patients is distinct and differentiates it from other diseases [4, 5].
In 2004, mutations in L2HGDH were shown to cause human L-2-HGA [3, 6]. L2HGDH is comprised of 10 exons which encode a protein of 463 amino acids that contains a N-terminal mitochondrial targeting sequence and C-terminal amino acid sequence homology to FAD-dependent oxidoreductases . L-2-hydroxyglutarate dehydrogenase is bound to mitochondrial membranes and catalyzes the conversion of L-2-hydroxyglutarate to α-ketoglutarate .
L-2-HGA was described in Staffordshire bull terriers in 2003 . These dogs presented with ataxia, dementia, tremors and seizures, and they showed MRI changes similar to the human disease. L-2-hydroxyglutaric acid levels were elevated in urine, cerebrospinal fluid and plasma from affected dogs. In 2007, Penderis et al.  identified a 2 bp substitution in exon 10 of L2HGDH predicting a two amino acid substitution in Staffordshire bull terriers affected with L-2-HGA. A case of L-2-HGA was also reported in a West Highland white terrier with clinical and MRI characteristics of the disease , but no molecular genetic cause was determined. In this report, we describe the clinical features and the likely molecular genetic cause of L-2-HGA in a Yorkshire terrier.
We genotyped 6 unaffected Yorkshire terriers and 97 dogs from other breeds at L2HGDH:c.1 by PCR-RFLP with PCR primers 5′-GCGCTCGATTGGCCCTTG-3′ and 5′-GCAGGCCAGCGGCTACTCAC-3′ which produced a 298 bp amplicon. The wild type allele was hydrolyzed by restriction enzyme NcoI into fragments of 157 and 141 bp; whereas, the mutant allele lacked the NcoI restriction site. All 103 normal dogs were homozygous for the wild type A allele.
L2HGDH encodes a FAD-dependent L-2-hydroxyglutarate dehydrogenase that is bound to mitochondrial membranes and converts L-2-hydroxyglutarate to α-ketoglutarate . L-2-hydroxyglutarate is endogenously produced but is not an intermediate of any currently recognized mammalian metabolic pathway. Instead, L-2-hydroxyglutarate is formed because mitochondrial L-malate dehydrogenase is not completely specific for oxaloacetate, its primary substrate. This enzyme can also reduce α-ketoglutarate to L-2-hydroxyglutarate as a side reaction . L-2-hydroxyglutarate dehydrogenase prevents the accumulation of L-2-hydroxyglutarate by FAD-dependent oxidation back to α-ketoglutarate. Thus, L-2-HGA is considered to be a deficiency of ‘metabolite repair’ [6, 15, 16].
The deleterious consequence of L-2-hydroxyglutarate dehydrogenase deficiency is the accumulation of L-2-hydroxyglutarate. L-2-hydroxyglutarate induces oxidative stress and inhibits mitochondrial creatine kinase in the cerebellum [17, 18]. Also, L-2-hydroxyglutarate is a structural analog of glutamate, and thus a potential inhibitor of the many biologic processes that involve this key metabolite and neurotransmitter . The exact mechanism by which accumulation of L-2-hydroxyglutaric acid causes brain injury is still unknown.
Since the identification of the first human L2HGDH mutations [3, 6], about 70 L-2-HGA-causing mutations have been reported . Among these are two that occur in the initiator codon (c.1A>C and c.1A>G), similar to the canine L2HGDH:c.1A>G mutation reported here. The canine initiator codon mutation was absent from 103 unaffected dogs. Mutations in initiator codons require the use of an alternative downstream methionine codon . The next potential translational start site in the canine L2HGDH is out of frame and would encode a peptide of only 4 amino acids before it reaches a stop codon. The first inframe methionine codon is located 183 codons downstream from the original start codon, which if used would encode a protein without the N-terminal mitochondrial targeting domain . Thus, the mutant L2HGDH in the Yorkshire terrier with L-2-HGA is unlikely to be functional.
The only clinical signs shown by the Yorkshire terrier were episodes of hyperactivity and aggression. At the time of this report, the dog has not shown any dementia, ataxia or generalized seizures as has been described in human patients and dogs with L-2-HGA from other breeds. Unless there is an unidentified splice variant that provides an alternative initiator methionine codon, the milder phenotype is unlikely to be due to residual enzyme activity. It could reflect a response to therapy or the younger age of the Yorkshire terrier. The decreased severity may have been due to the altered diet or to the phenobarbital therapy which would suggest that these episodes were complex partial seizures, possibly with post-ictal behavior changes.
We described a previously unreported mutation in L2HGDH in a Yorkshire terrier with L-2-HGA. This mutation is predicted to result in a non-functional gene. We recently learned that another group has independently found the same mutation in two European Yorkshire terriers with L-2-HGA . The occurrence of L-2-HGA in two European Yorkshire terriers with an identical mutation is additional evidence that the L2HGDH:c.1A>G transition is the cause of L-2-HGA in this breed. The similarities between canine L-2-HGA and the human disease suggest that the canine disease could be a useful model to understand the pathogenesis of the disease and to evaluate potential therapies.
1L/D, Hill’s Pet Nutrition, Inc., Topeka, KS, USA.
- Duran M, Kamerling JP, Bakker HD, van Gennip AH, Wadman SK: L-2-Hydroxyglutaric aciduria: an inborn error of metabolism?. J Inherit Metab Dis. 1980, 3: 109-112. 10.1007/BF02312543.View ArticlePubMedGoogle Scholar
- Barth PG, Hoffmann GF, Jaeken J, Lehnert W, Hanefeld F, Van Gennip AH, Duran M, Valk J, Schutgens RBH, Trefz FK, et al: L-2-hydroxyglutaric acidemia: a novel inherited neurometabolic disease. Ann Neurol. 1992, 32: 66-71. 10.1002/ana.410320111.View ArticlePubMedGoogle Scholar
- Topçu M, Jobard F, Halliez S, Coskun T, Yalçinkayal C, Gerceker FO, Wanders RJA, Prud’homme J-F, Lathrop M, Özguc M, Fischer J: L-2-Hydroxyglutaric aciduria: identification of a mutant gene C14orf160, localized on chromosome 14q22.1. Hum Mol Genet. 2004, 13: 2803-2811. 10.1093/hmg/ddh300.View ArticlePubMedGoogle Scholar
- Barbot C, Fineza I, Diogo L, Maria M, Melo J, Guimarães A, Melo Pires M, Luis Cardoso M, Vila rinho L: L-2-Hydroxyglutaric aciduria: clinical, biochemical and magnetic resonance imaging in six Portuguese pediatric patients. Brain Dev. 1997, 19: 268-273. 10.1016/S0387-7604(97)00574-3.View ArticlePubMedGoogle Scholar
- D’Incerti L, Farina L, Moroni I, Uziel G, Savoiardo M: L-2-Hydroxyglutaric aciduria: MRI in seven cases. Neuroradiology. 1998, 40: 727-733. 10.1007/s002340050673.View ArticlePubMedGoogle Scholar
- Rzem R, Veiga-da-Cunha M, Noël G, Goffette S, Nassogne M-C, Tabarki B, Schöller C, Marquardt T, Vikkula M, Van Schaftingen E: A gene encoding a putative FAD-dependent L-2-hydroxyglutarate dehydrogenase is mutated in L-2-hydroxyglutaric aciduria. Proc Natl Acad Sci U S A. 2004, 101: 16849-16854. 10.1073/pnas.0404840101.PubMed CentralView ArticlePubMedGoogle Scholar
- Abramson CJ, Platt SR, Jakobs C, Verhoeven NM, Dennis R, Garosi L, Shelton GD: L-2-Hydroxyglutaric aciduria in staffordshire bull terriers. J Vet Intern Med. 2003, 17: 551-556. 10.1111/j.1939-1676.2003.tb02477.x.View ArticlePubMedGoogle Scholar
- Penderis J, Calvin J, Abramson C, Jakobs C, Pettitt L, Binns MM, Verhoeven NM, O’Driscoll E, Platt SR, Mellersh CS: L-2-hydroxyglutaric aciduria: characterisation of the molecular defect in a spontaneous canine model. J Med Genet. 2007, 44: 334-340. 10.1136/jmg.2006.042507.PubMed CentralView ArticlePubMedGoogle Scholar
- Garosi LS, Penderis J, McConnell JF, Jacobs C: L-2-hydroxyglutaric aciduria in a West Highland white terrier. Vet Rec. 2005, 156: 145-147.View ArticlePubMedGoogle Scholar
- Hoffmann G, Aramaki S, Blum-Hoffmann E, Nyhan WL, Sweetman L: Quantitative analysis for organic acids in biological samples: batch isolation followed by gas chromatographic-mass spectrometric analysis. Clin Chem. 1989, 35: 587-595.PubMedGoogle Scholar
- Katz ML, Khan S, Awano T, Shahid SA, Siakotos AN, Johnson GS: A mutation in the CLN8 gene in English Setter dogs with neuronal ceroid-lipofuscinosis. Biochem Biophys Res Commun. 2005, 327: 541-547. 10.1016/j.bbrc.2004.12.038.View ArticlePubMedGoogle Scholar
- Farias FHG, Johnson GS, Taylor JF, Giuliano E, Katz ML, Sanders DN, Schnabel RD, McKay SD, Khan S, Gharahkhani P, et al: An ADAMTS17 splice donor site mutation in dogs with primary lens luxation. Investig Ophthalmol Vis Sci. 2010, 51: 4716-4721. 10.1167/iovs.09-5142.View ArticleGoogle Scholar
- Wolf A, Caliebe A, Thomas NST, Ball EV, Mort M, Stenson PD, Krawczak M, Cooper DN: Single base-pair substitutions at the translation initiation sites of human genes as a cause of inherited disease. Hum Mutat. 2011, 32: 1137-1143. 10.1002/humu.21547.View ArticlePubMedGoogle Scholar
- Rzem R, Vincent MF, Van Schaftingen E, Veiga-da-Cunha M: L-2-Hydroxyglutaric aciduria, a defect of metabolite repair. J Inherit Metab Dis. 2007, 30: 681-689. 10.1007/s10545-007-0487-0.View ArticlePubMedGoogle Scholar
- Van Schaftingen E, Rzem R, Veiga-da-Cunha M: L-2-Hydroxyglutaric aciduria, a disorder of metabolite repair. J Inherit Metab Dis. 2009, 32: 135-142. 10.1007/s10545-008-1042-3.View ArticlePubMedGoogle Scholar
- Struys E, Gibson K, Jakobs C: Novel insights into L-2-hydroxyglutaric aciduria: mass isotopomer studies reveal 2-oxoglutaric acid as the metabolic precursor of L-2-hydroxyglutaric acid. J Inherit Metab Dis. 2007, 30: 690-693. 10.1007/s10545-007-0697-5.View ArticlePubMedGoogle Scholar
- Latini A, Scussiato K, Borba Rosa R, Leipnitz G, Llesuy S, Belló-Klein A, Dutra-Filho CS, Wajner M: Induction of oxidative stress by L-2-hydroxyglutaric acid in rat brain. J Neurosci Res. 2003, 74: 103-110. 10.1002/jnr.10735.View ArticlePubMedGoogle Scholar
- da Silva CG, Bueno ARF, Schuck PF, Leipnitz G, Ribeiro CAJ, Wannmacher CMD, Wyse ATS, Wajner M: l-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase activity from cerebellum of developing rats. Int J Dev Neurosci. 2003, 21: 217-224. 10.1016/S0736-5748(03)00035-2.View ArticlePubMedGoogle Scholar
- Steenweg ME, Jakobs C, Errami A, van Dooren SJM, Adeva Bartolomé MT, Aerssens P, Augoustides-Savvapoulou P, Baric I, Baumann M, Bonafé L, et al: An overview of L-2-hydroxyglutarate dehydrogenase gene (L2HGDH) variants: a genotype–phenotype study. Hum Mutat. 2010, 31: 380-390. 10.1002/humu.21197.View ArticlePubMedGoogle Scholar
- Sanchez-Masian DAR, Mascort J, Jakobs C, Salomons G, Zamora A, Casado M, Fernandez M, Recio A, Luján Feliu-Pascual A: L-2-hydroxyglutaric aciduria in two female Yorkshire terriers. J Am Anim Hosp Assoc. 2012, in press.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.